Summary: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa, or rickettsiae), antigenic proteins derived from them, or synthetic constructs, administered for the prevention, amelioration, or treatment of infectious and other diseases.

Top Publications

  1. doi New adjuvants for human vaccines
    M Lamine Mbow
    Novartis Vaccines and Diagnostics, Cambridge, MA, USA
    Curr Opin Immunol 22:411-6. 2010
  2. pmc Vaccine adjuvants: putting innate immunity to work
    Robert L Coffman
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Immunity 33:492-503. 2010
  3. doi Use of defined TLR ligands as adjuvants within human vaccines
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA, USA
    Immunol Rev 239:178-96. 2011
  4. pmc CpG DNA as a vaccine adjuvant
    Christian Bode
    Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA
    Expert Rev Vaccines 10:499-511. 2011
  5. doi Key roles of adjuvants in modern vaccines
    Steven G Reed
    Infectious Disease Research Institute, Seattle, Washington, USA
    Nat Med 19:1597-608. 2013
  6. doi Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype
    Stacey L Demento
    Department of Biomedical Engineering, Yale University, New Haven, CT 06511, USA
    Biomaterials 33:4957-64. 2012
  7. pmc Reverse vaccinology: developing vaccines in the era of genomics
    Alessandro Sette
    La Jolla Institute for Allergy and Immunology, San Diego, CA 92130, USA
    Immunity 33:530-41. 2010
  8. doi Vaccines for the twenty-first century society
    Rino Rappuoli
    Novartis Vaccines and Diagnostics Srl, Via Fiorentina 5, 53100 Siena, Italy
    Nat Rev Immunol 11:865-72. 2011
  9. pmc Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity
    C Trumpfheller
    Laboratory of Cellular Physiology and Immunology and Chris Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York, NY 10065, USA
    J Intern Med 271:183-92. 2012
  10. doi Developing vaccines to combat hookworm infection and intestinal schistosomiasis
    Peter J Hotez
    Department of Microbiology, Immunology, and Tropical Medicine, George Washington University, Washington, DC 20037, USA
    Nat Rev Microbiol 8:814-26. 2010

Detail Information

Publications343 found, 100 shown here

  1. doi New adjuvants for human vaccines
    M Lamine Mbow
    Novartis Vaccines and Diagnostics, Cambridge, MA, USA
    Curr Opin Immunol 22:411-6. 2010
    ..This review highlights recent progress of clinically approved vaccine adjuvants and identifies potential novel adjuvants that can broaden the development of new vaccines against infectious diseases.
  2. pmc Vaccine adjuvants: putting innate immunity to work
    Robert L Coffman
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Immunity 33:492-503. 2010
    Adjuvants enhance immunity to vaccines and experimental antigens by a variety of mechanisms...
  3. doi Use of defined TLR ligands as adjuvants within human vaccines
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA, USA
    Immunol Rev 239:178-96. 2011
    ..Experience with first generation vaccines, as well as rapid advances in developing defined vaccines containing Toll-like receptor ligands (TLRLs), indicate ..
  4. pmc CpG DNA as a vaccine adjuvant
    Christian Bode
    Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA
    Expert Rev Vaccines 10:499-511. 2011
    ..Preclinical studies indicate that CpG ODNs improve the activity of vaccines targeting infectious diseases and cancer...
  5. doi Key roles of adjuvants in modern vaccines
    Steven G Reed
    Infectious Disease Research Institute, Seattle, Washington, USA
    Nat Med 19:1597-608. 2013
    b>Vaccines containing novel adjuvant formulations are increasingly reaching advanced development and licensing stages, providing new tools to fill previously unmet clinical needs...
  6. doi Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype
    Stacey L Demento
    Department of Biomedical Engineering, Yale University, New Haven, CT 06511, USA
    Biomaterials 33:4957-64. 2012
    Particulate vaccines are emerging promising technologies for the creation of tunable prophylactics against a wide variety of conditions...
  7. pmc Reverse vaccinology: developing vaccines in the era of genomics
    Alessandro Sette
    La Jolla Institute for Allergy and Immunology, San Diego, CA 92130, USA
    Immunity 33:530-41. 2010
    ..development of a vaccine against serogroup B meningococcus, and it is now being used for several other bacterial vaccines. In this review, we will first summarize the impact that genome sequencing has had on vaccine development, and ..
  8. doi Vaccines for the twenty-first century society
    Rino Rappuoli
    Novartis Vaccines and Diagnostics Srl, Via Fiorentina 5, 53100 Siena, Italy
    Nat Rev Immunol 11:865-72. 2011
    b>Vaccines have been one of the major revolutions in the history of mankind and, during the twentieth century, they eliminated most of the childhood diseases that used to cause millions of deaths...
  9. pmc Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity
    C Trumpfheller
    Laboratory of Cellular Physiology and Immunology and Chris Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York, NY 10065, USA
    J Intern Med 271:183-92. 2012
    Current vaccines primarily work by inducing protective antibodies. However, in many infections like HIV, malaria and tuberculosis as well as cancers, there remains a need for durable and protective T-cell immunity...
  10. doi Developing vaccines to combat hookworm infection and intestinal schistosomiasis
    Peter J Hotez
    Department of Microbiology, Immunology, and Tropical Medicine, George Washington University, Washington, DC 20037, USA
    Nat Rev Microbiol 8:814-26. 2010
    ..The development of vaccines for these infections could substantially reduce the global disability associated with these helminthiases...
  11. ncbi Reverse vaccinology
    R Rappuoli
    IRIS, Chiron S p A, Via Fiorentina 1, 53100, Siena, Italy
    Curr Opin Microbiol 3:445-50. 2000
    ..Many vaccines impossible to develop so far will become a reality...
  12. ncbi GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
    Nathalie Garçon
    GlaxoSmithKline Biologicals, Research and Development, 1330 Rixensart, Belgium
    Expert Rev Vaccines 6:723-39. 2007
    ..GSK) Biologicals to develop various Adjuvant Systems for the design of prophylactic and therapeutic vaccines. Adjuvant Systems are formulations of classical adjuvants mixed with immunomodulators, specifically adapted to ..
  13. doi Vaccines: correlates of vaccine-induced immunity
    Stanley A Plotkin
    Sanofi Pasteur, Doylestown, Pennsylvania, USA
    Clin Infect Dis 47:401-9. 2008
    The immune system is redundant, and B and T cells collaborate. However, almost all current vaccines work through induction of antibodies in serum or on mucosa that block infection or interfere with microbial invasion of the bloodstream...
  14. doi A small jab - a big effect: nonspecific immunomodulation by vaccines
    Christine S Benn
    Research Center for Vitamins and Vaccines CVIVA, Statens Serum Institut, Institute of Clinical Research, University of Southern Denmark, and Odense University Hospital, Denmark Electronic address
    Trends Immunol 34:431-9. 2013
    Recent epidemiological studies have shown that, in addition to disease-specific effects, vaccines against infectious diseases have nonspecific effects on the ability of the immune system to handle other pathogens...
  15. pmc Understanding immunosenescence to improve responses to vaccines
    Jorg J Goronzy
    The Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA
    Nat Immunol 14:428-36. 2013
  16. pmc Designing vaccines based on biology of human dendritic cell subsets
    Karolina Palucka
    Baylor Institute for Immunology Research, 3434 Live Oak Avenue, Dallas, TX 75204, USA
    Immunity 33:464-78. 2010
    The effective vaccines developed against a variety of infectious agents, including polio, measles, and hepatitis B, represent major achievements in medicine...
  17. doi Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism
    Cristofer S Price
    Abt Associates Inc, Cambridge, MA, USA
    Pediatrics 126:656-64. 2010
    Exposure to thimerosal, a mercury-containing preservative that is used in vaccines and immunoglobulin preparations, has been hypothesized to be associated with increased risk of autism spectrum disorder (ASD)...
  18. doi Plant-made vaccines for humans and animals
    Edward P Rybicki
    Department of Molecular and Cell Biology, University of Cape Town, Rondebosch, South Africa ed rybicki uct ac za
    Plant Biotechnol J 8:620-37. 2010
    The concept of using plants to produce high-value pharmaceuticals such as vaccines is 20 years old this year and is only now on the brink of realisation as an established technology...
  19. ncbi Mucosal immunity and vaccines
    Jan Holmgren
    Department of Medical Microbiology and Immunology and Göteborg University Vaccine Research Institute, Goteborg University, SE 405 30 Goteborg, Sweden
    Nat Med 11:S45-53. 2005
    There is currently great interest in developing mucosal vaccines against a variety of microbial pathogens...
  20. doi Unmet needs in modern vaccinology: adjuvants to improve the immune response
    Geert Leroux-Roels
    Centre for Vaccinology, Ghent University and Hospital, Belgium
    Vaccine 28:C25-36. 2010
    ..New vaccine technology has led to vaccines containing highly purified antigens with improved tolerability and safety profiles, but the immune response they ..
  21. doi Chloroplast-derived vaccines against human diseases: achievements, challenges and scopes
    Andreas G Lössl
    Department of Applied Plant Sciences and Plant Biotechnology DAPP, University of Natural Resources and Applied Life Sciences BOKU, Vienna, Austria
    Plant Biotechnol J 9:527-39. 2011
    ..For this reason, different options can be considered for the production of affordable vaccines. Plants have been proved as an alternative expression system for various compounds of biological importance...
  22. pmc Systems biology approaches to new vaccine development
    Ann L Oberg
    Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States
    Curr Opin Immunol 23:436-43. 2011
    ..applying this approach and its resulting data to expand our knowledge base and drive directed development of new vaccines. We also provide applied examples and point out new directions for the field in order to illustrate the power of ..
  23. pmc Immunology of gut mucosal vaccines
    Marcela F Pasetti
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore St, Room 480, Baltimore, MD 21201, USA
    Immunol Rev 239:125-48. 2011
    ..oral immunization and the cross-talk between mucosal and systemic immunity should expedite the development of vaccines to diminish the global burden caused by enteric pathogens...
  24. doi Cationic liposomes as vaccine adjuvants
    Dennis Christensen
    Statens Serum Institut, Department of Infectious Disease Immunology, Copenhagen, Denmark
    Expert Rev Vaccines 10:513-21. 2011
    ..In this article we review the recent progress on the application of cationic liposomes as vaccine delivery systems/adjuvants...
  25. ncbi Targeting dendritic cells with biomaterials: developing the next generation of vaccines
    Sai T Reddy
    Institute of Bioengineering, Ecole Polytechnique Federale de Lausanne EPFL, CH 1015 Lausanne, Switzerland
    Trends Immunol 27:573-9. 2006 both efficacy and practicality: many chronic diseases cannot yet be addressed by vaccination, and several vaccines that do function well require multiple injections, which is a substantial limitation in various parts of the ..
  26. ncbi Chitosan as a novel nasal delivery system for vaccines
    L Illum
    West Pharmaceutical Services, Drug Delivery and Clinical Research Centre Ltd, Albert Einstein Centre, Nottingham Science and Technology Park, NG7 2TN, Nottingham, UK
    Adv Drug Deliv Rev 51:81-96. 2001
    ..our work on the use of the cationic polysaccharide, chitosan as a delivery system for nasally administered vaccines. Several animal studies have been carried out on influenza, pertussis and diphtheria vaccines with good results...
  27. ncbi Adjuvants designed for veterinary and human vaccines
    J Aucouturier
    Seppic 75, Quai d Orsay, 75321 Cedex 07, Paris, France
    Vaccine 19:2666-72. 2001
    Adjuvants play an important role in the efficacy of vaccines as the antigens become more and more purified. Indeed recombinant proteins or synthetic peptides are safer than crude inactivated micro-organism, but less immunogenic...
  28. ncbi Epitope mapping: the first step in developing epitope-based vaccines
    Jonathan M Gershoni
    Department of Cell Research and Immunology, Tel Aviv University, Tel Aviv, Israel
    BioDrugs 21:145-56. 2007
    ..Thus, understanding the antibody/epitope interaction provides a basis for the rational design of preventive vaccines. It is assumed that immunization with the precise epitope, corresponding to an effective neutralizing antibody, ..
  29. ncbi Epitope-based vaccines: an update on epitope identification, vaccine design and delivery
    Alessandro Sette
    La Jolla Institute for Allergy and Immunology, San Diego, California 92121, USA
    Curr Opin Immunol 15:461-70. 2003
    ..Recent advances in understanding the mechanisms of immunodominance thus represent an opportunity to further develop the epitope-based approach...
  30. ncbi Vaccines against intracellular infections requiring cellular immunity
    R A Seder
    Clinical Immunology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 406:793-8. 2000
    b>Vaccines against a variety of infectious diseases represent one of the great triumphs of medicine. The immune correlates of protection induced by most current vaccines seem to be mediated by long-lived humoral immune responses...
  31. doi Solar-powered factories for new vaccines and antibiotics
    Ralph Bock
    Max Planck Institut fur Molekulare Pflanzenphysiologie, Am Muhlenberg 1, D 14476 Potsdam Golm, Germany
    Trends Biotechnol 28:246-52. 2010
    ..has been made with the chloroplast-based production of two particularly important classes of pharmaceuticals: vaccines and antibiotics...
  32. pmc Carbohydrate vaccines: developing sweet solutions to sticky situations?
    Rena D Astronomo
    Department of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA
    Nat Rev Drug Discov 9:308-24. 2010
    ..Here, we review the progress being made in addressing challenges posed by targeting the surface carbohydrates of bacteria, protozoa, helminths, viruses, fungi and cancer cells for vaccine purposes...
  33. doi Effective induction of high-titer antibodies by viral vector vaccines
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
    Nat Med 14:819-21. 2008
    Protein-in-adjuvant vaccines have shown limited success against difficult diseases such as blood-stage malaria...
  34. doi Viruses as vaccine vectors for infectious diseases and cancer
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK
    Nat Rev Microbiol 8:62-73. 2010
    ..Viral-vector vaccines remain the best means to induce cellular immunity and are now showing promise for the induction of strong humoral ..
  35. doi Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis
    Gabrielle Pauli
    University Hospital, Strasbourg, France
    J Allergy Clin Immunol 122:951-60. 2008
    Recombinant DNA technology has the potential to produce allergen-specific immunotherapy vaccines with defined composition.
  36. ncbi Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach
    Anne des Rieux
    Universite Catholique de Louvain, Unite de Pharmacie Galenique, avenue E Mounier, 73 20, 1200 Brussels, Belgium
    J Control Release 116:1-27. 2006
    ..Encouraging results upon in vivo testing are reported but low bioavailability and lack of control on absorbed dose slow down products development. Vaccines are certainly the most promising applications for orally delivered nanoparticles.
  37. doi New vaccines for neglected parasitic diseases and dengue
    Coreen M Beaumier
    Sabin Vaccine Institute and Texas Children s Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston 77030, Tex, USA
    Transl Res 162:144-55. 2013
    ..Preventative and therapeutic NTD vaccines are needed as long-term solutions...
  38. pmc Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats
    M Pravetoni
    Minneapolis Medical Research Foundation, 600 Shapiro Building, 914 8th Street, Minneapolis, MN 55404, USA
    Vaccine 30:4617-24. 2012
    Opioid conjugate vaccines have shown promise in animal models as a potential treatment for opioid addiction. Individual vaccines are quite specific and each targets only a limited number of structurally similar opioids...
  39. doi Biology of immune responses to vaccines in elderly persons
    Birgit Weinberger
    Immunology Division, Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria
    Clin Infect Dis 46:1078-84. 2008
    ..Improved vaccination strategies, new adjuvants, and new vaccines that specifically target the aged immune system will help to overcome the limitations of immunosenescence and ..
  40. pmc Vaccines against drug abuse
    X Y Shen
    Immunology Allergy and Rheumatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Clin Pharmacol Ther 91:60-70. 2012
    The currently available medications for the treatment of drug abuse have had only limited success. Anti-addiction vaccines, aimed at eliciting antibodies that block the pharmacological effects of drugs, have great potential for treating ..
  41. pmc Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines
    Eynav Klechevsky
    Baylor Institute for Immunology Research, Dallas, Texas, USA
    Hum Immunol 70:281-8. 2009
    ..The biologic raison d'être for separate DC subsets has been the focus of many studies including our own and is being reviewed with an emphasis on human skin DCs...
  42. doi Integrating experimental (in vitro and in vivo) neurotoxicity studies of low-dose thimerosal relevant to vaccines
    Jose G Dorea
    Faculty of Health Sciences, Universidade de Brasilia, CP 04322, 70919 970, Brasilia, DF, Brazil
    Neurochem Res 36:927-38. 2011
    ..pregnant mothers, newborns and young children who must receive repeated doses of Thimerosal-containing vaccines (TCVs)...
  43. doi Mucosal vaccines: recent progress in understanding the natural barriers
    Olga Borges
    Centre for Neuroscience and Cell Biology and Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000 548, Coimbra, Portugal
    Pharm Res 27:211-23. 2010
    ..The development of vaccines for mucosal application requires antigen delivery systems and immunopotentiators that efficiently facilitate the ..
  44. ncbi Production and proteomic characterization of pharmaceutical-grade Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts for allergy vaccines
    Thierry Batard
    Recherche et Developpement, Stallergènes, Antony, France
    Int Arch Allergy Immunol 140:295-305. 2006
    ..Hence large quantities of well-characterized HDM extracts are needed to prepare pharmaceutical-grade allergy vaccines. To this aim, the present study was undertaken to define optimal conditions for large-scale cultures.
  45. pmc Formulation of vaccines containing CpG oligonucleotides and alum
    Joan A Aebig
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Rockville, MD, 20852 USA
    J Immunol Methods 323:139-46. 2007
    CpG oligodeoxynucleotides are potent immunostimulants. For parenterally delivered alum-based vaccines, the immunostimulatory effect of CpG depends on the association of the CpG and antigen to the alum...
  46. ncbi Immunization without needles
    Samir Mitragotri
    Department of Chemical Engineering, University of California, Santa Barbara, California 93106, USA
    Nat Rev Immunol 5:905-16. 2005
    ..This article focuses on contemporary developments in needle-free methods of immunization, such as liquid-jet injectors, topical application to the skin, oral pills and nasal sprays...
  47. pmc Targeting human dendritic cell subsets for improved vaccines
    Hideki Ueno
    Baylor Institute for Immunology Research, Baylor Research Institute, 3434 Live Oak, Dallas, TX 75204, USA
    Semin Immunol 23:21-7. 2011
    ..These progresses in our understanding of DC biology provide a new framework for improving human health. In this review, we discuss human DC subsets in the context of their medical applications, with a particular focus on DC targeting...
  48. pmc Substance abuse vaccines
    Frank M Orson
    Veterans Affairs Medical Center, Houston, TX 77030, USA
    Ann N Y Acad Sci 1141:257-69. 2008
    ..Although several potential mechanisms for the effects of antidrug vaccines have been suggested, the most straightforward and intuitive mechanism involves binding of the drug by antibodies ..
  49. doi Particulate vaccines: on the quest for optimal delivery and immune response
    Marie Luce De Temmerman
    Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, B 9000 Ghent, Belgium
    Drug Discov Today 16:569-82. 2011
    Subunit vaccines offer a safer alternative to traditional organism-based vaccines, but their immunogenicity is impaired. This hurdle might be overcome by the use of micro- and nanodelivery systems carrying the antigen(s)...
  50. ncbi Epitope identification and discovery using phage display libraries: applications in vaccine development and diagnostics
    Lin Fa Wang
    CSIRO Livestock Industries, Australian Animal Health Laboratory, Geelong 3220, Victoria, Australia
    Curr Drug Targets 5:1-15. 2004
    ..Instead, this review aims to focus on specific applications related to the discovery and identification of epitopes which have potential as vaccine candidates or can be used in disease diagnosis...
  51. doi Vaccines and the future of human immunology
    Ronald N Germain
    Lymphocyte Biology Section and Program in Systems Immunology and Infectious Disease Modeling, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1892, USA
    Immunity 33:441-50. 2010
    ..a collection of detailed reviews summarizes needs, opportunities, and roadblocks to the development of new vaccines, all in the context of our current knowledge and understanding of key aspects of immune function and microbial ..
  52. pmc CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells
    Alice W Yewdall
    Cancer Institute, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 5:e11144. 2010
    ..To overcome this problem, autologous DCs are generated ex vivo, loaded with tumor antigens, and activated in this non-suppressive environment before administration to patients. However, DC-based vaccines rarely induce tumor regression.
  53. doi Improving the performance of enteric vaccines in the developing world
    Andrew C Serazin
    The Global Health Program, The Bill and Melinda Gates Foundation, Seattle, WA, USA
    Nat Immunol 11:769-73. 2010
    b>Vaccines against important enteric pathogens such as rotavirus and poliovirus have shown lower efficacy in some populations...
  54. ncbi Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA
    Jan Holmgren
    Department of Medical Microbiology and Immunology and Göteborg University Vaccine Research Institute GUVAX, Goteborg University, P O Box 435, SE 40530 Goteborg, Sweden
    Immunol Lett 97:181-8. 2005
    ..The development of mucosal vaccines, whether for prevention of infectious diseases or for oral tolerance immunotherapy, requires efficient antigen ..
  55. ncbi Anti-tick vaccines
    P Willadsen
    CSIRO Livestock Industries, Queensland Bioscience Precinct, 306 Carmody Road, St Lucia, Queensland 4067, Australia
    Parasitology 129:S367-87. 2004
    ..The existence of two commercial vaccines has allowed a number of field studies showing that the existing products can make an important contribution to an ..
  56. pmc Controlling endemic cholera with oral vaccines
    Ira M Longini
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS Med 4:e336. 2007
    ..Internationally licensed, killed whole-cell based oral cholera vaccines (OCVs) have been available for over a decade, but have not been used for the control of cholera...
  57. doi New horizons in adjuvants for vaccine development
    Steven G Reed
    Infectious Disease Research Institute, 1124 Columbia St Suite 400, Seattle, WA 98104, USA
    Trends Immunol 30:23-32. 2009
    Over the last decade, there has been a flurry of research on adjuvants for vaccines, and several novel adjuvants are now in licensed products or in late stage clinical development...
  58. ncbi Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics
    M B Irving
    Department of Molecular Biology and Biochemistry, Simon Fraser University, BC V5A 1S6, Burnaby, Canada
    Curr Opin Chem Biol 5:314-24. 2001
    ..These may prove useful for diagnosis and, possibly, in determining disease etiology...
  59. ncbi Aluminum salts in vaccines--US perspective
    Norman W Baylor
    Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Bethesda, MD, USA
    Vaccine 20:S18-23. 2002 the form of aluminum hydroxide, aluminum phosphate or alum has been commonly used as an adjuvant in many vaccines licensed by the US Food and Drug Administration. Chapter 21 of the US Code of Federal Regulations [610...
  60. doi Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity
    Tracy L Flach
    Immunology Research Group, Department of Microbiology and Infectious Diseases, and Snyder Institute, University of Calgary, Calgary, Alberta, Canada
    Nat Med 17:479-87. 2011
    ..This study therefore suggests an unexpected mechanism for how this crystalline structure interacts with the immune system and how the DC plasma membrane may behave as a general sensor for solid structures...
  61. ncbi Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond
    Vidadi Yusibov
    Fraunhofer USA Center for Molecular Biotechnology, Newark, DE, USA
    Hum Vaccin 7:313-21. 2011
    ..This builds on two decades of research, starting with transgenic approaches to develop oral vaccines in which antigens or therapeutics can be delivered in processed plant biomass, and progressing to transient ..
  62. doi Designing the next generation of vaccines for global public health
    Fabio Bagnoli
    Novartis Vaccines and Diagnostics, Siena, Italy
    OMICS 15:545-66. 2011
    ..emergence of multidrug resistant bacteria; (3) the need for improving the safety of the more traditional licensed vaccines; and finally, (4) the great promise for innovative vaccine design and research with convergence of omics sciences,..
  63. ncbi Aluminium compounds for use in vaccines
    Erik B Lindblad
    Adjuvant Department, Brenntag Biosector, DK 3600 Frederikssund, Denmark
    Immunol Cell Biol 82:497-505. 2004
    Aluminium adjuvants are the most widely used adjuvants in both human and veterinary vaccines. These adjuvants have been used in practical vaccination for more than 60 years and are generally recognized as safe and as stimulators of Th2 ..
  64. pmc A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses
    Tomonori Nochi
    Division of Mucosal Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108 8639, Japan
    J Exp Med 204:2789-96. 2007
    ..The use of NKM 16-2-4 to target vaccine antigens to the M cell-specific carbohydrate moiety is a new strategy for developing highly effective mucosal vaccines.
  65. pmc Smallpox vaccines: targets of protective immunity
    Bernard Moss
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3210, USA
    Immunol Rev 239:8-26. 2011
    ..with the present susceptibility of unimmunized populations have spurred the development of new-generation vaccines that are safer than the original and can be produced by modern methods...
  66. doi Vaccine adjuvants: current challenges and future approaches
    Jennifer H Wilson-Welder
    Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, Iowa 50011, USA
    J Pharm Sci 98:1278-316. 2009
    ..A comprehensive discussion is presented of current vaccine adjuvants, their effects on the induction of immune responses, and vaccine adjuvants that have shown promise in recent literature...
  67. pmc Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements
    Else Marie Agger
    Adjuvant Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    PLoS ONE 3:e3116. 2008
    It is now emerging that for vaccines against a range of diseases including influenza, malaria and HIV, the induction of a humoral response is insufficient and a substantial complementary cell-mediated immune response is necessary for ..
  68. pmc Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination
    David A Zaharoff
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, United States
    Vaccine 25:2085-94. 2007
    The development of safe, novel adjuvants is necessary to maximize the efficacy of new and/or available vaccines. Chitosan is a non-toxic, biocompatible, biodegradable, natural polysaccharide derived from the exoskeletons of crustaceans ..
  69. ncbi Saponin-adjuvanted particulate vaccines for clinical use
    Caroline D Skene
    Centre for Animal Biotechnology, University of Melbourne, Melbourne, VIC 3010, Australia
    Methods 40:53-9. 2006
    ..These particulate vaccines retain the adjuvant activity of the saponin component but without toxicity...
  70. pmc Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination
    Tomonori Nochi
    Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, University of Tokyo, Tokyo 108 8639, Japan
    Proc Natl Acad Sci U S A 104:10986-91. 2007
    ..Because they require neither refrigeration (cold-chain management) nor a needle, these rice-based mucosal vaccines offer a highly practical and cost-effective strategy for orally vaccinating large populations against mucosal ..
  71. ncbi Identification and characterization of a full-length cDNA encoding paramyosin of Trichinella spiralis
    Jing Yang
    Department of Parasitology, School of Basic Medical Sciences, Capital Medical University, 10 Xitoutiao, You An Men, Beijing 100069, PR China
    Biochem Biophys Res Commun 365:528-33. 2008
    ..These studies showed that rTs-Pmy induced protective immunity in mice and could be considered as a potential vaccine candidate for trichinellosis...
  72. pmc Vaccines: from empirical development to rational design
    Christine Rueckert
    Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany
    PLoS Pathog 8:e1003001. 2012
    ..Furthermore, most currently available vaccines were empirically designed...
  73. pmc Systems vaccinology: learning to compute the behavior of vaccine induced immunity
    Helder I Nakaya
    Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, GA, USA
    Wiley Interdiscip Rev Syst Biol Med 4:193-205. 2012 biology is being applied to vaccinology, with the goal of: (1) understanding the mechanisms by which vaccines stimulate protective immunity, and (2) predicting the immunogenicity or efficacy of vaccines...
  74. pmc Tick vaccines and the control of tick-borne pathogens
    Octavio Merino
    SaBio, Instituto de Investigación en Recursos Cinegéticos IREC CSIC UCLM JCCM Ciudad Real, Spain
    Front Cell Infect Microbiol 3:30. 2013
    ..In this article, we review the tick-protective antigens that have been identified for the formulation of tick vaccines and the effect of these vaccines on the control of tick-borne pathogens.
  75. doi Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity
    M Focke
    Christian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology, Center for Pathophysiology, Immunology and Infectiology, Immunology and Infectiology, Medical University of Vienna, Vienna, Austria
    Clin Exp Allergy 40:385-97. 2010
    ..poor quality of natural allergen extracts, which are the active ingredients of all currently available allergy vaccines. Because of the progress made in the field of molecular allergen characterization, new allergy vaccines based on ..
  76. ncbi Helminthes could influence the outcome of vaccines against TB in the tropics
    D Elias
    Armauer Hansen Research Institute, Addis Ababa, Ethiopia
    Parasite Immunol 28:507-13. 2006
    ..This information would also be of great relevance in the design of vaccines against diseases of major public health importance, including malaria and HIV/AIDS.
  77. pmc T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein
    Emily K Forbes
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 7:e44943. 2012
    Viral vectored vaccines have been shown to induce both T cell and antibody responses in animals and humans...
  78. pmc Cytokines: the future of intranasal vaccine adjuvants
    Afton L Thompson
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Clin Dev Immunol 2011:289597. 2011
    Due to its potential as an effective, needle-free route of immunization for use with subunit vaccines, nasal immunization continues to be evaluated as a route of immunization in both research and clinical studies...
  79. doi Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells
    Gerty Schreibelt
    Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Blood 116:564-74. 2010
    Currently dendritic cell (DC)-based vaccines are explored in clinical trials, predominantly in cancer patients...
  80. doi Chitosan-based delivery systems for mucosal vaccines
    Inderjit Jabbal-Gill
    Archimedes Development Ltd, Albert Einstein Centre, Nottingham Science and Technology Park, University Boulevard, Nottingham, UK
    Expert Opin Drug Deliv 9:1051-67. 2012
    ..Chitosan-based delivery systems are reviewed here as they address these issues and hence represent the most promising candidates for the delivery of mucosal vaccines.
  81. doi The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine
    Miriam Tendler
    Fundacao Oswaldo Cruz, Laboratório de Esquistossomose Experimental, Av Brasil, 4365, Manguinhos, Rio de Janeiro, RJ, CEP 21 045 900, Brazil Institute FIOCRUZ, Brazil
    Acta Trop 108:263-6. 2008
    ..With regard to schistosomiasis, more than 10 important antigens with strong potential as vaccines candidates emerged from the several 100 scientific projects supported by international donor agencies and ..
  82. doi Protective efficacy of bacterial membranes containing surface-exposed BM95 antigenic peptides for the control of cattle tick infestations
    Mario Canales
    Instituto de Investigacion en Recursos Cinegeticos IREC CSIC UCLM JCCM, Ronda de Toledo s n, 13005 Ciudad Real, Spain
    Vaccine 27:7244-8. 2009
    ..coli and suggests the possibility of using recombinant bacterial membrane fractions for vaccination against cattle tick infestations...
  83. doi Optimizing efficacy of mucosal vaccines
    Ayman Gebril
    University of Strathclyde, Strathclyde Institute of Pharmacy and Biomedical Sciences SIPBS, Glasgow, Scotland, UK
    Expert Rev Vaccines 11:1139-55. 2012
    In general, there are only a few vaccines administered via mucosal routes, as the mucosal immune system presents numerous hurdles, including diversity in mucosal surface structure, complexity in immune cell interaction and limitations in ..
  84. doi During the 'decade of vaccines,' the lives of 6.4 million children valued at $231 billion could be saved
    Sachiko Ozawa
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Health Aff (Millwood) 30:1010-20. 2011
    ..In this article we explore the benefits of expanding the delivery of life-saving vaccines in seventy-two low- and middle-income countries, which we estimate would prevent the deaths of 6...
  85. pmc Intradermal delivery of vaccines: potential benefits and current challenges
    J K Hickling
    Tandem Ltd, Cambridge, England
    Bull World Health Organ 89:221-6. 2011
    ..This is known as dose-sparing and has been demonstrated in clinical trials with some, but not all, vaccines. Dose-sparing could be beneficial to immunization programmes by potentially reducing the costs of purchase, ..
  86. ncbi Effector and memory T-cell differentiation: implications for vaccine development
    Susan M Kaech
    Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Nat Rev Immunol 2:251-62. 2002
    ..Models of the pathways of effector and memory T-cell differentiation are discussed, and we highlight the implications of this new understanding for the optimization of vaccine strategies...
  87. pmc Vaccines to combat the neglected tropical diseases
    Jeffrey M Bethony
    Microbiology, Immunology, and Tropical Medicine, George Washington University Medical Center, Washington, DC 20037, USA
    Immunol Rev 239:237-70. 2011
    ..Despite their global public health importance, progress on developing vaccines for NTD pathogens has lagged because of some key technical hurdles and the fact that these infections occur ..
  88. ncbi Mucosal vaccines: the promise and the challenge
    Marian R Neutra
    GI Cell Biology Research Laboratory, Children s Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Immunol 6:148-58. 2006
    ..induced by mucosal immunization through oral, nasal, rectal or vaginal routes, but the vast majority of vaccines in use today are administered by injection...
  89. doi A decade of vaccines: Integrating immunology and vaccinology for rational vaccine design
    David A D'Argenio
    Global Health Discovery, Global Health Program, Bill and Melinda Gates Foundation, PO Box 23350, Seattle, WA 98102, USA
    Immunity 33:437-40. 2010
    ..New approaches will be needed, however, to develop highly effective vaccines to prevent tuberculosis, HIV-AIDS, and malaria and to eradicate polio...
  90. doi What the world's religions teach, applied to vaccines and immune globulins
    John D Grabenstein
    Merck Vaccines, 770 Sumneytown Pike, WP97 B364, West Point, PA 19426, USA
    Vaccine 31:2011-23. 2013
    ..a temple not to be defiled' is contrasted with other teaching and quality-control requirements in manufacturing vaccines and immune globulins...
  91. doi Vaccines against diseases transmitted from animals to humans: a one health paradigm
    Thomas P Monath
    One Health Initiative Pro Bono Team, United States 1 Austria PaxVax Inc, United States Electronic address
    Vaccine 31:5321-38. 2013
    ..Three frameworks for the use of vaccines in this context are described, and examples are provided of successes and failures...
  92. pmc Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers
    Irina Esterlis
    Department of Psychiatry, Yale University, New Haven, Conneticut, USA
    Am J Psychiatry 170:399-407. 2013
    ..This likely contributes to maintenance of smoking dependence and cessation difficulty. Developing nicotine vaccines could improve treatments...
  93. pmc Molecular Pharming: future targets and aspirations
    Mathew Paul
    Molecular Immunology Unit, Research Centre for Infection and Immunity, St George s Hospital Medical School, London, UK
    Hum Vaccin 7:375-82. 2011 in the prevention of infectious diseases, particular in underdeveloped countries where access to medicines and vaccines has historically been limited. This is why, at St...
  94. doi Self-report compared to electronic medical record across eight adult vaccines: do results vary by demographic factors?
    S J Rolnick
    HealthPartners Institute for Education and Research, P O Box 1524, Minneapolis, MN 55440 1524, USA
    Vaccine 31:3928-35. 2013 comprehensively assess the validity of self-reported adult vaccination status for the eight most common adult vaccines we conducted a survey of vaccination receipt and compared it to the electronic medical record (EMR), which was ..
  95. doi Thimerosal exposure in early life and neuropsychological outcomes 7-10 years later
    John P Barile
    Department of Psychology, Georgia State University, USA
    J Pediatr Psychol 37:106-18. 2012
    The authors used a public use data set to investigate associations between the receipt of thimerosal-containing vaccines and immune globulins early in life and neuropsychological outcomes assessed at 7-10 years.
  96. pmc Immune effector mechanisms against schistosomiasis: looking for a chink in the parasite's armour
    R Alan Wilson
    Department of Biology, University of York, PO Box 373, York YO10 5YW, UK
    Trends Parasitol 25:423-31. 2009
    ..In addition, ways need to be found of keeping the immune system on permanent alert, either to achieve adequate inhibition of protein function in adults, or because a trickle of incoming parasites does not amplify the secondary response...
  97. doi "IDEAL" vaccines for resource poor settings
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Vaccine 29:D116-25. 2011
    In developing countries, immunization delivery would be more efficient, safer and economical if all vaccines could elicit long-term protection following needle-free administration of just a single dose and without need for a cold chain, ..
  98. doi Vaccine and Immunization Surveillance in Ontario (VISION) - using linked health administrative databases to monitor vaccine safety
    Kumanan Wilson
    Ottawa Hospital, Civic Campus, 1053 Carling Avenue, Administrative Services Building, Room 1009, Box 684, Ottawa, ON K1Y 4E9, Canada
    Vaccine 30:6115-20. 2012
    ..conducted population based self-controlled case series analyses to evaluate the safety of recommended pediatric vaccines in the general population and in specific subgroups...
  99. pmc High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants
    Xinyuan Chen
    Wellman Center for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, Boston, MA 02114, United States
    Vaccine 31:159-64. 2012
    ..for tobacco addiction may offer a safe, alternative treatment if the immunogenicity of the current nicotine vaccines can be improved...
  100. doi The next decade of vaccines: societal and scientific challenges
    E Richard Moxon
    University of Oxford Department of Paediatrics, John Radcliffe Hospital, Oxford, UK
    Lancet 378:348-59. 2011
    b>Vaccines against microbial diseases have improved the health of millions of people...
  101. doi Immunomodulators as adjuvants for vaccines and antimicrobial therapy
    Erin F Nicholls
    Center for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, British Columbia, Canada
    Ann N Y Acad Sci 1213:46-61. 2010
    ..The effectiveness of many vaccines currently in use is due in part to adjuvants, molecules that have little immunogenicity by themselves but which ..

Research Grants76

  1. CFI Pathogen Inactivation Technology
    Trevor P Castor; Fiscal Year: 2010
    ..developed technology will also be applicable to recombinant therapeutics, monoclonal antibodies, transgenics and vaccines. PUBLIC HEALTH RELEVANCE: There are a number of emerging viruses such as West Nile, Ebola, SARS, potential ..
  2. Vaccine Development for Falciparum Malaria in Pregnant Women and Their Offspring
    Ian C Michelow; Fiscal Year: 2013
    ..Michelow's research goal for the proposed Mentored Career Development Award is to discover new anti-malarial vaccines for women of childbearing age in order to protect their highly vulnerable offspring from severe or fatal malaria ..
  3. Importance of antigen specific immunoglobulin responses in controlling SIV/SHIV i
    Bapi Pahar; Fiscal Year: 2010
    ..that HIV-1 impairs protective immunoglobulin G (IgG) and immunoglobulin A (IgA) responses against pathogens and vaccines by inducing progressive loss of these CD4+ T helper cells...
  4. Natural History and Prevention of Viral Hepatitis Among Alaska Natives
    BRIAN JAMES MCMAHON; Fiscal Year: 2013
    ..issues by determining the further duration of vaccine protection afforded by both hepatitis A and hepatitis B vaccines in children and adults in well-established longitudinal cohorts...
  5. Metabolic Engineering of Bacteria for Cancer Immunotherapy by Gamma Delta T Cells
    Craig T Morita; Fiscal Year: 2013
    ..No group has attempted to metabolically engineer bacteria to derive 34 vaccines. We now propose to develop new vaccines for V32V42 T cell cancer immunotherapy by metabolic engineering ..
  6. Mucosal Immunity, Vaccines and Microbiota Interplay in Humans and Animal
    Marcelo B Sztein; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Vaccines are widely viewed as cost-effective interventions to prevent and control classical endemic and epidemic infectious diseases, as well as to limit the transmission and impact of emerging ..
  7. N-methanocarbathymidine (N-MCT) for the Treatment of Herpes and Pox Virus Infecti
    Aquilur Rahman; Fiscal Year: 2010
    ..6B that would allow the government to serve as the investment partner for emerging companies focusing on new vaccines or drugs as the next generation countermeasures against anthrax, smallpox and other agents...
    Terence S Dermody; Fiscal Year: 2013
    ..This gap in knowledge has impeded the rational design of antiviral agents and vaccines that act at the earliest stages of infection...
    David Allen; Fiscal Year: 2009
    ..Biologics Testing Biological products (commonly referred to as biologics) include vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, monoclonal antibodies, and ..
  10. Novel PET imaging agents for early diagnosis of plaque deposition in Alzheimer's
    Padmakar Kulkarni; Fiscal Year: 2010
    ..Researchers are working on the development of vaccines and other treatment options...
  11. Transgenesis and Xenotransplantation
    Jorge A Piedrahita; Fiscal Year: 2013
    ..development and treatment for diseases such as leukemia, looking at disease progression and the development of vaccines for diseases such as AIDS, and study human tumor progression and treatment...
  12. Molecular Mechanisms of Parvovirus Gene Expression and Replication
    Jianming Qiu; Fiscal Year: 2013
    ..At present, no specific antiviral drugs or vaccines (that prevent B19V infection in high-risk groups) are available...
  13. Nanopolymersomes for Transcutaneous Co-Delivery of Vaccine Antigens and Adjuvants
    PAUL CAMILLE TUMEH; Fiscal Year: 2013
    ..vaccine strategies by addressing two scientific barriers: 1) increasing the versatility and efficacy of current vaccines by enhancing cell-mediated immunity through targeting of the epidermal Langerhans cells (LCs), and 2) enabling ..
  14. Novel DNA-Launched Attenuated Vaccine for VEE Virus
    PETER M PUSHKO; Fiscal Year: 2012
    ..The efforts to develop new VEEV vaccines are underway...
  15. Recombinant Attenuated Salmonella Vaccines for Humans
    Roy Curtiss; Fiscal Year: 2012
    ..vaccine development program based on our recent technical developments in using recombinant attenuated Salmonella vaccines (RASV)...
  16. Cellular Immunity to Category A-C Viruses in Humans
    ROBERT WILLIAM FINBERG; Fiscal Year: 2013
    ..project is to define the human T-cell responses to influenza infection and to trivalent inactivated influenza vaccines (TIV) in younger and older adults...
  17. The Neuroimmunology of Viral Infection
    DANIEL J CARR; Fiscal Year: 2013
    ..In so doing, a focus on the development of vaccines that utilize (via expansion or activation) such components will provide superior efficacy compared to current ..
  18. A quantitative proteomics approach to understand viral immune evasion strategies
    Michele E Hardy; Fiscal Year: 2010
    ..and the key players, both viral and host, have garnered such focus because of the potential to develop attenuated vaccines consisting of viruses with weakened evasion strategies...
  19. Interdisciplinary Research Training in Reproduction for Indian Fellows
    John C Herr; Fiscal Year: 2010
    ..factors acting in the testis and epididymis, spermicides, infertility diagnostics, and contraceptive vaccines based on sperm and egg antigens...
  20. Salmonella Vaccines Against Bacterial Enteropathogens
    Roy Curtiss; Fiscal Year: 2013
    ..We propose to use these technologies to develop vaccines to prevent/reduce diarrheal diseases caused by bacterial enteropathogens in agriculturally important animals and ..
  21. Present Homologous and Heterologous Antigen with Hepatitis E Virus
    R Holland Cheng; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Advantages of DNA vaccines including well-tolerance, safety and ability to induce antibody, cytotoxic T- lymphocytes, and T-helper immune responses make it more and more attractive in treatment of ..
  22. Development of Vaccines against Clostridium difficile Infection
    SAUL R TZIPORI; Fiscal Year: 2013
    ..provided by applicant): This proposal is in response to RFA-AI-09-016 requesting applications to develop vaccines for selected pathogens including Clostridium difficile, the cause of pseudomembranous colitis, which accounts for ..
  23. Novel Bioconjugate Vaccines to Prevent Staphylococcus aureus Infection
    JEAN CLAIRE LEE; Fiscal Year: 2013
    ..firm in Switzerland, has developed a proprietary technology that enables the manufacture of bioconjugate vaccines based on complex polysaccharide structures...
    Rafi Ahmed; Fiscal Year: 2013 use genomics to define molecular signatures of a successful vaccine, and to use this knowledge to develop new vaccines against emerging infections...
  25. Inhibiting Mucosal HIV-1 Transmission by Host Cell RNA Interference
    Alexandra L Howell; Fiscal Year: 2013
    ..infection could augment other therapeutic approaches designed to reduce mucosal HIV-1 transmission, including vaccines and microbicides...
  26. Characterizing TLR Function of Human Dendritic Cells in the Elderly
    Alexander Panda; Fiscal Year: 2012
    ..resulting in increased susceptibility to viral and bacterial infections and decreased response to vaccines. While it is likely that comorbid conditions contribute to the observed increase in mortality, it is clear that ..
  27. Nanoemulsion-based vaccine for chronic hepatitis B virus
    James R Baker; Fiscal Year: 2010
    ..However, the current vaccines while generally effective are less useful in high-risk populations with renal disease or other immunological ..
  28. Regulation of vaccine-induced anti-fungal T17 cells
    MARCEL WUETHRICH; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Vaccines against infectious disease have been hailed as the greatest achievement in public health over the last century...
  29. Killed But Metabolically Active Leishmania: a novel protozoan vaccine technology
    Noah Craft; Fiscal Year: 2009
    ..against Leishmania and other protozoa remains an elusive target, and there are still no effective vaccines approved for use against protozoan diseases...
  30. Vitamin A adjuvant to enhance gut immunity and rotavirus vaccines in neonates
    Linda J Saif; Fiscal Year: 2010
    ..Newly licensed oral RV vaccines have unproven or lower efficacies in infants in impoverished countries...
  31. Screening Complete TB Proteome for Protective Antigens
    Alan Greener; Fiscal Year: 2010
    ..Mtb) genome, yielding a pool of protective antigens that will immediately enter development as subunit vaccines for tuberculosis...
  32. Knockdown of Gene Expression in Immune Cells in Humanized Mice
    Judy Lieberman; Fiscal Year: 2010
    ..hypothesis that enhancing TFH cells and suppressing Treg cells augments the humoral response to two HIV candidate vaccines, a gp120 subunit vaccine and whole killed virus...
  33. Mucosal Memory T Cells at the Vanguard of Human Host Defense
    Donna L Farber; Fiscal Year: 2010
    ..will fill a notable gap in our knowledge of human immune responses at mucosal sites that is crucial for designing vaccines to generate efficacious and long-lasting mucosal immune responses...
    Vivian Bellofatto; Fiscal Year: 2010
    ..At present, there are no vaccines to protect humans from trypanosomal infections and current drugs are toxic, ineffective and expensive...
  35. Thirteenth Annual Meeting of the Rocky Mountain Virology Association
    Joel Rovnak; Fiscal Year: 2013
    ..e. RNA stability and Flavivirus biology. The topics discussed include medical virology (vaccines, epidemiology, viral zoonoses), arthropod-borne diseases (RNA viruses and RNA metabolism, viral vectors and ..
  36. Moffitt Skin Cancer SPORE
    Jeffrey S Weber; Fiscal Year: 2013
    ..We expect that data from Project 4 will justify developing new prevention trials of vaccines for HPV and MCPV to prevent squamous and/or basal cell cancers of the skin...
  37. Modulation of host immune defense by Pneumocystis beta-glucans
    EVA MARIA CARMONA PORQUERA; Fiscal Year: 2013 potential role as a potent vaccine adjuvant it could also be applied to other fungal, bacterial and viral vaccines, to enhance protection...
  38. Vaccine Assembly from Surface Proteins of Staphylococcus Aureus
    Olaf Schneewind; Fiscal Year: 2013
    ..aureus disease has been a goal since the discovery of this microbe. Whole-cell live or killed vaccines, however, failed to generate protective immune responses in humans and, because of safety concerns, are no longer ..
  39. Membrane Ion-channels in Helminth Parasites: Anthelmintic Resistance and Sites of
    RICHARD JOHN MARTIN; Fiscal Year: 2011
    ..and treatment of these parasitic diseases relies on the use of anthelmintic drugs because no effective vaccines are available;but, there are real concerns that mass chemotherapy will lead to development of resistance...
  40. Mechanisms and Enviromental Determinants of Rhinovirus Illness Severity
    James E Gern; Fiscal Year: 2013
    ..Unfortunately, no treatments or vaccines are available for HRV infections...
  41. Regulation of Human Papillomavirus Replication via Cell Signaling Pathways
    ANASTACIA GRIEGO; Fiscal Year: 2013
    ..Although prophylactic vaccines are very effective in preventing infection by HPV-16 and HPV-18, the uptake of the vaccines is poor in the US and ..
  42. NOX1 and NOX2 as Therapeutic Targets in Influenza
    JOHN DAVID LAMBETH; Fiscal Year: 2013
    ..rates of mutation and recombination that soon renders immunization ineffective and requires yearly production of vaccines. In addition, up to 85% of isolates are resistant to available antiviral molecules targete against the virus ..
  43. Mucosal Immunity and Influenza Vaccines: Phenotype and Role of Activated B Cells
    HARRY BERNARD GREENBERG; Fiscal Year: 2010
    ..Influenza vaccines, including live attenuated influenza vaccine (LAIV) given via intranasal spay and trivalent inactivated influenza ..
  44. Evolution of the Immune Response to Cytomegalovirus Transmitted via Breast Milk
    Lynn Puddington; Fiscal Year: 2010
    ..Vaccine development to prevent cytomegalovirus disease: report from the national vaccine advisory committee", Vaccines 39:233)...
    David R Brown; Fiscal Year: 2010 drug targets for the modulation of mucosal immune responses to HIV and other gut pathogens as well as oral vaccines offering protection from these microbes...
  46. Development of a Recombinant Tetravalent Dengue Vaccine Based on a Subunit Envelo
    Lynda G Tussey; Fiscal Year: 2013
    ..Live attenuated or chimeric virus-based vaccines are promising but they struggle with inadequate attenuation or an imbalanced immune response due to interference...
    Stephen M Beverley; Fiscal Year: 2010
    ..Currently, there are no vaccines available against leishmaniasis, and the only approved chemotherapies are marginally effective, difficult to ..
    William M Nauseef; Fiscal Year: 2013
    ..and elements of innate host defense in general, and provide potential targets for novel pharmacologic agents and vaccines. Learning how to engage more fully innate immune responses to F...
  49. Human cytomegalovirus entry into epithelial and endothelial cells
    David C Johnson; Fiscal Year: 2013
    ..viral and cellular entry mediators is key to a better understanding of HCMV pathogenesis and for the design of vaccines and anti-virals...
  50. Mechanisms of adaptive immunity to P. aeruginosa in the lung
    Gregory P Priebe; Fiscal Year: 2013
    ..number of lung T cells, can be found at higher levels in bronchoalveolar lavage fluid compared with control vaccines, and is associated with more rapid recruitment of neutrophils to the airways...
  51. Control of alphavirous replacation in the nervous system
    Diane E Griffin; Fiscal Year: 2013
    ..There are no treatments for these infections and vaccines are not available for most...
  52. Gold Nanoparticle Assisted Delivery of Cancer Vaccines and Immune Stimulants
    Adam Lin; Fiscal Year: 2013
    ..Cancer vaccines utilize the immune system to generate a sustainable and specific anti-tumor response, providing a promising means ..
  53. Enterovirus RNA Translation and Replication
    David J Barton; Fiscal Year: 2013
    ..Insights supported by the proposed investigation will be important for designing safe and effective vaccines and novel antiviral drugs for PV and other picornaviruses...
  54. A common denominator of pathogenesis;a rare opportunity for novel therapeutic de
    DOUGLAS ALAN MITCHELL; Fiscal Year: 2011
    ..Perhaps most important were the discovery of antibiotics for bacterial infections and effective vaccines for several major viruses...
  55. Combination Clostridium Difficile Toxin and Adhesin Vaccine
    Ciaran P Kelly; Fiscal Year: 2013
    ..Several promising experimental vaccines have been tested with flagellin either as an antigen or as an adjuvant...
  56. HIFU-enhanced tumor vaccines
    Chandan Guha; Fiscal Year: 2012
    ..Immunotherapy with tumor vaccines has the potential to induce a tumor-specific immune response that enables the body's own immune system to ..
  57. Programming of Protective CD8 T-Cell Memory by Live and Adjuvanted Subunit Vaccin
    Marulasiddappa Suresh; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Live attenuated vaccines have been highly effective in controlling human infections such as smallpox, yellow fever, measles, mumps, rubella, and chicken pox...
  58. Pathogenesis of Oxidative Stress in Chagas Disease
    Nisha Jain Garg; Fiscal Year: 2013
    ..However, no vaccines or safe drugs are available for treatment of an estimated >300,000 patients in the US and >10 million ..
  59. New Investigation Initiatives for the Prevention of Complications of Thalassemia
    Ellis J Neufeld; Fiscal Year: 2011
    ..program modeled on the Do the Five strategy used by hemophilia centers and CDC to promote comprehensive care, vaccines for blood-borne viruses, adequate chelation, and blood safety monitoring...
  60. Adhesion of Leptospira interrogans to Human Cell Surface Receptors
    Jenifer L Coburn; Fiscal Year: 2010
    ..goal of this project is to better understand the nature and consequences of Leptospira interactions with mammalian cells, which may eventually be useful in future development of novel vaccines or therapeutic approaches.
  61. Preclinical studies of a heroin/morphine vaccine for opiate addiction
    Paul R Pentel; Fiscal Year: 2013
    ..b>Vaccines for nicotine and cocaine addictions are in clinical trials and preliminary data suggest efficacy...
  62. Moraxella catarrhalis: virulence-based prevention
    Timothy F Murphy; Fiscal Year: 2013
    ..The widespread use of pneumococcal conjugate vaccines in children since 2000 has caused an increased prevalence of colonization and infection by M. catarrhalis...
  63. Crystalline Endolysin Treatment for Tuberculosis in TB/HIV co-infected patients
    BHAMI C SHENOY; Fiscal Year: 2012
    ..It is impractical to eliminate TB without novel, and more effective drugs, diagnostics and vaccines. The world immediately needs simpler and faster curative drugs;safer and effective drugs that can treat all forms ..
  64. Regional Biocontainment Laboratory
    Charles Bailey; Fiscal Year: 2007
    ..program will focus on the development of animal models, host-pathogen relationships, aerobiology, and testing of vaccines and therapeutics against aerosol challenge in a Good Laboratory Practices (GLP) environment...
  65. Plant-Derived hepatitis B Vaccine from Biomanufacturing System to Clinical Trial
    Robert Britt; Fiscal Year: 2009
    ..cut costs of production of many current biotherapeutics and will encourage development of new drugs and vaccines that can be genetically inserted into the genome of certain plants...
  66. Synthetic saccharides to study immunological properties of Streptococcus pneumoni
    Alexei V Demchenko; Fiscal Year: 2010 a variety of damaging and healing processes has already been acknowledged by development of carbohydrate-based vaccines and therapeutics...
  67. Macaque model of TB/AIDS co-infection via natural routes of exposure
    Deepak Kaushal; Fiscal Year: 2010
    ..The world-wide AIDS situation is equally gloomy. The frontline candidate vaccines against AIDS have failed in clinical trials...
  68. Function of NALT in nasal immunization to heterotypic strains of influenza
    Troy D Randall; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Cold adapted influenza vaccines (CAV) are live attenuated viruses that infect the upper respiratory tract, including the Nasal Associated Lymphoid Tissue (NALT)...
    Linda Saif; Fiscal Year: 2006
    ..complexity of RV and the need to induce intestinal immunity in infants have impeded development of effective RV vaccines. Because the exact nature and extent of cross-protection to RV serotypes is not clearly characterized, there is ..
  70. Research and Development of a Novel System to Produce Polysaccharide Conjugate Va
    Peng Wang; Fiscal Year: 2009
    Polysaccharide conjugate vaccines are proving to be an effective means to generate protective immune responses so as to prevent a wide range of diseases...
  71. ApoVax104-HPV as a Novel Vaccine for Cervical Cancer
    KATHRYN MACLEOD; Fiscal Year: 2009
    ..Unlike most cancers, cervical cancer is caused by a virus - the human papillomavirus (HPV). Two preventative vaccines against HPV were recently licensed in the United States. Merck &Co...
  72. Structural Studies of HBsAg: Support for Quentin Florence
    QUENTIN FLORENCE; Fiscal Year: 2009 of the HBsAg major neutralizing antigenic epitope and (2) impeded the development of bivalent vaccines where HBsAg is used as a carrier for foreign antigenic epitopes...
  73. Pilot trial of a DNA vaccine encoding PAP in patients with prostate cancer
    Douglas McNeel; Fiscal Year: 2009
    ..The goal of this research is to develop anti-prostate tumor vaccines as a treatment for cancer, and specifically prostate cancer...
  74. Mechanisms of non-neutralizing antibody-mediated protection from influenza virus
    DENISE KAMINSKI; Fiscal Year: 2009
    ..per year. Humans can be protected by vaccination against seasonal influenza strains. However, current influenza vaccines mostly induce antibodies to the virus'external glycoproteins...
  75. Dual Antigen Nanoparticle Vaccine System For Bacillus Infectious Disease
    Puthupparampil Scaria; Fiscal Year: 2009
    Development of rationally designed vaccines is an important need that nanotechnology has tremendous potential to transform. Already nanoparticle developments are incorporated into approved small molecule therapeutics...
  76. Adjuvants for Agile Vaccine Development
    Philip Felgner; Fiscal Year: 2006
    Because of the potential bioterrorism threat, the development of safe and effective vaccines against the infectious microorganisms on the select agents list is a national and worldwide goal...